Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.


Home > Oncology > ESMO 2019 > Lung Cancer > First-line osimertinib significantly lengthens OS in NSCLC

First-line osimertinib significantly lengthens OS in NSCLC

Presented by
Prof. Suresh Ramalingam, Emory University, Atlanta, USA
Conference
ESMO 2019
Trial
Phase 3, FLAURA
    Prof. Suresh Ramalingam (Emory University, Atlanta, USA) presented the final overall survival (OS) data of the FLAURA trial in the first Presidential Symposium. First-line osimertinib significantly lengthened overall survival compared with first generation EGFR TKIs (gefitinib or erlotinib) in patients with advanced non–small cell lung cancer (NSCLC) harbouring Ex19del/L858R EGFR mutation [1].

    The primary endpoint of progression free survival (PFS) was previously reported [2]. Final overall survival results were presented (58% maturity): the median OS with osimertinib was 38.6 months vs 31.8 months with first generation EGFR TKIs, with a hazard ratio of 0.799 (P=0.0462; see Table). More than half (54%) of patients in the osimertinib group were alive at 3 years compared with 44% in the standard care group.

    Table. Efficacy results of the FLAURA trial



    Prof. Ramalingam noted that after disease progression, 31% of patients in the control group crossed over to the osimertinib arm, representing 47% of patients in the control group that received post-study therapy. He concluded: “FLAURA met both its primary and key secondary endpoints and showed a favourable safety profile for osimertinib. The results further reinforce the clinical utility and superiority of osimertinib in the front-line setting. Based on these data, osimertinib should be the preferred front-line therapy for EGFR-mutated lung cancer patients.”

    1. Ramalingam SS. ESMO Congress 2019. Abstract LBA5_PR.
    2. Soria JC, et al. N Engl J Med. 2018;378:113–125.




    Posted on